SCHEMBL6188701

SCHEMBL6188701

COCCNC1=C(Cl)C(=O)c2ccccc2C1=O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.83
NPSR1 Q6W5P4 5/20 0.83
MAPK1 P28482 4/20 0.83
NSD2 O96028 6/20 0.66
TDP1 Q9NUW8 3/20 0.66
HSP90AA1 P07900 3/20 0.66
L3MBTL1 Q9Y468 2/20 0.66
CASP3 P42574 2/20 0.66
SENP8 Q96LD8 2/20 0.66
SENP7 Q9BQF6 2/20 0.66
SENP6 Q9GZR1 2/20 0.66
BLM P54132 2/20 0.66
KDM4E B2RXH2 2/20 0.66
CDC25A P30304 6/20 0.65
HTT P42858 5/20 0.64
LMNA P02545 5/20 0.64
MITF O75030 4/20 0.64
ALDH1A1 P00352 3/20 0.64
USP2 O75604 1/20 0.64
POLB P06746 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15906861 0.82 MAPT (0.75) MAPTNPSR1MAPK1NSD2TDP1
SCHEMBL22413322 0.82 CDC25A (0.66) MAPTNPSR1MAPK1NSD2TDP1
SCHEMBL31277646 0.79 MAPT (0.72) MAPTNPSR1MAPK1NSD2TDP1
SCHEMBL17249976 0.79 CDC25A (1.00) MAPTNPSR1MAPK1NSD2TDP1
SCHEMBL17249965 0.78 MAPT (1.00) MAPTNPSR1MAPK1NSD2TDP1
SCHEMBL31029510 0.78 MAPT (0.66) MAPTNPSR1MAPK1NSD2TDP1
SCHEMBL10894074 0.78 MAPT (0.66) MAPTNPSR1MAPK1NSD2TDP1
SCHEMBL7962344 0.78 MAPT (0.70) MAPTNPSR1MAPK1NSD2TDP1
SCHEMBL6190075 0.78 MAPT (0.54) MAPTNPSR1MAPK1HSP90AA1L3MBTL1
SCHEMBL12283411 0.76 CDC25A (0.71) MAPTNPSR1MAPK1NSD2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180099917-A1 REVERSIBLY REDUCIBLE MATERIALS AND USE THEREOF UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2018-04-12 US disclosed
EP-1256576-B1 FUSED IMIDAZOLIUM DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2005-06-15 EP disclosed
US-6734203-B2 ANTI-CANCERS AND ANTITUMOR AGENTS ASTELLAS PHARMA INC. (JP) 2004-05-11 US disclosed
US-20030114508-A1 Fused imidazolium derivatives ASTELLAS PHARMA INC. (JP) 2003-06-19 US disclosed
EP-1256576-A1 FUSED IMIDAZOLIUM DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2002-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099917-A1 REVERSIBLY REDUCIBLE MATERIALS AND USE THEREOF NES, CBR3, SQOR MAPT 4120/4885NPSR1 1209/4885MAPK1 2109/4885
US-20030114508-A1 Fused imidazolium derivatives TP53, HRAS, BCOR MAPT 4795/4885NPSR1 4494/4885MAPK1 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.